A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets

Alexandra Vaiana; Jonathan Behr; Ryan Birol; Cornelis Blauwendraat; Bradford Casey; Kushan Chowdhury; Martin Citron; Joshua Crapser; Victoria Dardov; Fiona Ducotterd; Sonya Dumanis; John Dunlop; Michelle Durborow; Brian Fiske; Jessica Golden; Jonas Hannestad; Wendy Hung; Jennifer Kemp; Robin Kleiman; Adam Knight; Andrew Koemeter-Cox; Bruce Leuchter; Bejamin A. Logsdon; Rita Marreiros; Julie E. Miller; Amanda Mitchell; Pooja Mukherjee; Grace Navarro; Matthew R. Nelson; Karoly Nikolich; Tom Otis; Nicole Polinski; Shima Rastegar-Pouyani; Alastair D. Reith; Ekemini Riley; Lee Rubin; Mina Ryten; Jessica Sadick; Tina Schwabe; Todd Sherer; Sarah Silvergleid; Andrew Singleton; Lara St. Clair; Jan Stoehr; David J. Stone; Julianna Sullivan; Nicole Tanenbaum; Elisa Tinelli; Kate Trimble; Yifei Wang; Stacie Weninger; Nicolás Wiggenhauser; Stephen Wood; Darryle Schoepp; Virginie Buggia-Prevot; Shalini Padmanabhan; Gaia Skibinski

doi:10.1038/s41531-025-01039-3

A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets

Alexandra Vaiana
, Jonathan Behr
, Ryan Birol
, Cornelis Blauwendraat
, Bradford Casey
, Kushan Chowdhury
, Martin Citron
, Joshua Crapser
, Victoria Dardov
, Fiona Ducotterd
, Sonya Dumanis
, John Dunlop
, Michelle Durborow
, Brian Fiske
, Jessica Golden
, Jonas Hannestad
, Wendy Hung
, Jennifer Kemp
, Robin Kleiman
, Adam Knight

Andrew Koemeter-Cox, Bruce Leuchter, Bejamin A. Logsdon, Rita Marreiros, Julie E. Miller, Amanda Mitchell, Pooja Mukherjee, Grace Navarro, Matthew R. Nelson, Karoly Nikolich, Tom Otis, Nicole Polinski, Shima Rastegar-Pouyani, Alastair D. Reith, Ekemini Riley, Lee Rubin, Mina Ryten, Jessica Sadick, Tina Schwabe, Todd Sherer, Sarah Silvergleid, Andrew Singleton, Lara St. Clair, Jan Stoehr, David J. Stone, Julianna Sullivan, Nicole Tanenbaum, Elisa Tinelli, Kate Trimble, Yifei Wang, Stacie Weninger, Nicolás Wiggenhauser, Stephen Wood, Darryle Schoepp, Virginie Buggia-Prevot, Shalini Padmanabhan, Gaia Skibinski

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Identifying effective therapeutic targets for Parkinson’s disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson’s Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.

Original language	English (US)
Article number	179
Journal	npj Parkinson's Disease
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41531-025-01039-3
State	Published - Dec 2025

ASJC Scopus subject areas

Neurology
Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1038/s41531-025-01039-3

Cite this

Vaiana, A., Behr, J., Birol, R., Blauwendraat, C., Casey, B., Chowdhury, K., Citron, M., Crapser, J., Dardov, V., Ducotterd, F., Dumanis, S., Dunlop, J., Durborow, M., Fiske, B., Golden, J., Hannestad, J., Hung, W., Kemp, J., Kleiman, R., ... Skibinski, G. (2025). A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets. npj Parkinson's Disease, 11(1), Article 179. https://doi.org/10.1038/s41531-025-01039-3

Vaiana, A, Behr, J, Birol, R, Blauwendraat, C, Casey, B, Chowdhury, K, Citron, M, Crapser, J, Dardov, V, Ducotterd, F, Dumanis, S, Dunlop, J, Durborow, M, Fiske, B, Golden, J, Hannestad, J, Hung, W, Kemp, J, Kleiman, R, Knight, A, Koemeter-Cox, A, Leuchter, B, Logsdon, BA, Marreiros, R, Miller, JE, Mitchell, A, Mukherjee, P, Navarro, G, Nelson, MR, Nikolich, K, Otis, T, Polinski, N, Rastegar-Pouyani, S, Reith, AD, Riley, E, Rubin, L, Ryten, M, Sadick, J, Schwabe, T, Sherer, T, Silvergleid, S, Singleton, A, St. Clair, L, Stoehr, J, Stone, DJ, Sullivan, J, Tanenbaum, N, Tinelli, E, Trimble, K, Wang, Y, Weninger, S, Wiggenhauser, N, Wood, S, Schoepp, D, Buggia-Prevot, V, Padmanabhan, S & Skibinski, G 2025, 'A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets', npj Parkinson's Disease, vol. 11, no. 1, 179. https://doi.org/10.1038/s41531-025-01039-3

@article{12ddc5d5b52e4ca787bf48dc93c66944,

title = "A community-led initiative to de-risk and advance Parkinson{\textquoteright}s disease therapeutic targets",

abstract = "Identifying effective therapeutic targets for Parkinson{\textquoteright}s disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson{\textquoteright}s Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.",

author = "Alexandra Vaiana and Jonathan Behr and Ryan Birol and Cornelis Blauwendraat and Bradford Casey and Kushan Chowdhury and Martin Citron and Joshua Crapser and Victoria Dardov and Fiona Ducotterd and Sonya Dumanis and John Dunlop and Michelle Durborow and Brian Fiske and Jessica Golden and Jonas Hannestad and Wendy Hung and Jennifer Kemp and Robin Kleiman and Adam Knight and Andrew Koemeter-Cox and Bruce Leuchter and Logsdon, \{Bejamin A.\} and Rita Marreiros and Miller, \{Julie E.\} and Amanda Mitchell and Pooja Mukherjee and Grace Navarro and Nelson, \{Matthew R.\} and Karoly Nikolich and Tom Otis and Nicole Polinski and Shima Rastegar-Pouyani and Reith, \{Alastair D.\} and Ekemini Riley and Lee Rubin and Mina Ryten and Jessica Sadick and Tina Schwabe and Todd Sherer and Sarah Silvergleid and Andrew Singleton and \{St. Clair\}, Lara and Jan Stoehr and Stone, \{David J.\} and Julianna Sullivan and Nicole Tanenbaum and Elisa Tinelli and Kate Trimble and Yifei Wang and Stacie Weninger and Nicol{\'a}s Wiggenhauser and Stephen Wood and Darryle Schoepp and Virginie Buggia-Prevot and Shalini Padmanabhan and Gaia Skibinski",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = dec,

doi = "10.1038/s41531-025-01039-3",

language = "English (US)",

volume = "11",

journal = "npj Parkinson's Disease",

issn = "2373-8057",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets

AU - Vaiana, Alexandra

AU - Behr, Jonathan

AU - Birol, Ryan

AU - Blauwendraat, Cornelis

AU - Casey, Bradford

AU - Chowdhury, Kushan

AU - Citron, Martin

AU - Crapser, Joshua

AU - Dardov, Victoria

AU - Ducotterd, Fiona

AU - Dumanis, Sonya

AU - Dunlop, John

AU - Durborow, Michelle

AU - Fiske, Brian

AU - Golden, Jessica

AU - Hannestad, Jonas

AU - Hung, Wendy

AU - Kemp, Jennifer

AU - Kleiman, Robin

AU - Knight, Adam

AU - Koemeter-Cox, Andrew

AU - Leuchter, Bruce

AU - Logsdon, Bejamin A.

AU - Marreiros, Rita

AU - Miller, Julie E.

AU - Mitchell, Amanda

AU - Mukherjee, Pooja

AU - Navarro, Grace

AU - Nelson, Matthew R.

AU - Nikolich, Karoly

AU - Otis, Tom

AU - Polinski, Nicole

AU - Rastegar-Pouyani, Shima

AU - Reith, Alastair D.

AU - Riley, Ekemini

AU - Rubin, Lee

AU - Ryten, Mina

AU - Sadick, Jessica

AU - Schwabe, Tina

AU - Sherer, Todd

AU - Silvergleid, Sarah

AU - Singleton, Andrew

AU - St. Clair, Lara

AU - Stoehr, Jan

AU - Stone, David J.

AU - Sullivan, Julianna

AU - Tanenbaum, Nicole

AU - Tinelli, Elisa

AU - Trimble, Kate

AU - Wang, Yifei

AU - Weninger, Stacie

AU - Wiggenhauser, Nicolás

AU - Wood, Stephen

AU - Schoepp, Darryle

AU - Buggia-Prevot, Virginie

AU - Padmanabhan, Shalini

AU - Skibinski, Gaia

PY - 2025/12

Y1 - 2025/12

N2 - Identifying effective therapeutic targets for Parkinson’s disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson’s Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.

AB - Identifying effective therapeutic targets for Parkinson’s disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson’s Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.

UR - https://www.scopus.com/pages/publications/105008654727

UR - https://www.scopus.com/pages/publications/105008654727#tab=citedBy

U2 - 10.1038/s41531-025-01039-3

DO - 10.1038/s41531-025-01039-3

M3 - Article

AN - SCOPUS:105008654727

SN - 2373-8057

VL - 11

JO - npj Parkinson's Disease

JF - npj Parkinson's Disease

IS - 1

M1 - 179

ER -

A community-led initiative to de-risk and advance Parkinson’s disease therapeutic targets

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this